#iHeardSTL #FDA #GLP1 Have a question, comment, or feedback
Missing data on key clinical factors (such as body mass index and type 2 diabetes duration) may contribute to residual confounding, leaving uncertainty about whether the observed association is causal
This mix-up could lead to patients taking the wrong medication, posing risks such as ineffective treatment, drug interactions, or potential side effects
The inclusion criteria were as follows: the study type must be an RCT
The combination creates serious risks including hypoglycaemia, dehydration, nutritional deficiencies, and worsening gastrointestinal side effects, as Mounjaro already significantly reduces appetite and food intake
Muscle preservation: Most weight lost was body fat rather than lean tissue, though some muscle loss is expected with any significant weight reduction